European BioSafety Association

Last updated

The European BioSafety Association (EBSA) is a non-profit organization, founded in June 1996, which provides a forum to its members to discuss and debate issues of concern and to represent those working in the field of biosafety and associated activities. Its mission is to enhance knowledge and understanding of biological safety throughout Europe and the world.

See also

Sources

Related Research Articles

<span class="mw-page-title-main">Biotechnology</span> Use of living systems and organisms to develop or make useful products

Biotechnology is a multidisciplinary field that involves the integration of natural sciences and engineering sciences in order to achieve the application of organisms, cells, parts thereof and molecular analogues for products and services.

<span class="mw-page-title-main">Pfizer</span> American multinational pharmaceutical and biotechnology corporation

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. The company was established in 1849 in New York by two German entrepreneurs, Charles Pfizer (1824–1906) and his cousin Charles F. Erhart (1821–1891).

<span class="mw-page-title-main">Biosafety level</span> Level of the biocontainment precautions required to isolate dangerous biological agents

A biosafety level (BSL), or pathogen/protection level, is a set of biocontainment precautions required to isolate dangerous biological agents in an enclosed laboratory facility. The levels of containment range from the lowest biosafety level 1 (BSL-1) to the highest at level 4 (BSL-4). In the United States, the Centers for Disease Control and Prevention (CDC) have specified these levels in a publication referred to as BMBL. In the European Union, the same biosafety levels are defined in a directive. In Canada the four levels are known as Containment Levels. Facilities with these designations are also sometimes given as P1 through P4, as in the term P3 laboratory.

<i>Fédération Internationale de lAutomobile</i> International sport governing body

The Fédération Internationale de l'Automobile is an association established on 20 June 1904 to represent the interests of motoring organisations and motor car users. It is the governing body for many auto racing events, including Formula One. The FIA also promotes road safety around the world.

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) is an initiative that brings together regulatory authorities and pharmaceutical industry to discuss scientific and technical aspects of pharmaceutical product development and registration. The mission of the ICH is to promote public health by achieving greater harmonisation through the development of technical Guidelines and requirements for pharmaceutical product registration.

In the experimental (non-clinical) research arena, good laboratory practice or GLP is a quality system of management controls for research laboratories and organizations to ensure the uniformity, consistency, reliability, reproducibility, quality, and integrity of products in development for human or animal health through non-clinical safety tests; from physio-chemical properties through acute to chronic toxicity tests.

<span class="mw-page-title-main">European Federation of Pharmaceutical Industries and Associations</span> Brussels-based trade association

The European Federation of Pharmaceutical Industries and Associations (EFPIA) is a Brussels-based trade association and lobbying organisation, founded in 1978 and representing the pharmaceutical industry operating in Europe. Through its membership of 36 national associations and 39 leading pharmaceutical companies, the EFPIA represents 1,900 European companies.

Nimotuzumab is a humanized monoclonal antibody that as of 2014 had orphan status in the US and EU for glioma, and marketing approval in India, China, and other countries for squamous cell carcinomas of the head and neck, and was undergoing several clinical trials.

<span class="mw-page-title-main">European Directorate for the Quality of Medicines & HealthCare</span> International organisation

The European Directorate for the Quality of Medicines & HealthCare (EDQM) is a Directorate of the Council of Europe that traces its origins and statutes to the Convention on the Elaboration of a European Pharmacopoeia.

The Sub-Aqua Association or SAA is a diver training organization for scubadivers in the United Kingdom. The SAA and other UK-based diving groups have traditionally used a club-based system with unpaid instructors, while other training agencies organise most of their training programs through professional instructors and dive shops. The other major club-based diving organizations in the UK are the British Sub-Aqua Club (BSAC) and the Scottish Sub Aqua Club, and the principal non-club-based organisation is PADI.

European Business Aviation Association, or EBAA, is a non-profit association based in Belgium that has existed since 1977. It’s more than 700 member companies span all aspects of the business aviation sector in Europe and elsewhere. The EBAA's aim is to promote excellence and professionalism among its members and to ensure that aviation is properly recognized as a vital sector of the European Economy. EBAA represents corporate operators, commercial operators, manufacturers, airports, fixed-base operators, and business aviation service providers.

The World Recreational Scuba Training Council (WRSTC) was founded in 1999 and is dedicated to creating minimum recreational diving training standards for the various scuba diving certification agencies across the world. The WRSTC restricts its membership to national or regional councils. These councils consist of individual training organizations who collectively represent at least 50% of the annual diver certifications in the member council's country or region. A national council is referred to as a RSTC.

CropLife International is an international trade association of agrochemical companies founded in 2001. It was previously known as Global Crop Protection Federation and started out as International Group of National Associations of Manufacturers of Agrochemical Products in 1967. Its members include the world's largest agricultural biotechnology and agricultural pesticide businesses namely BASF, Bayer CropScience, Corteva, FMC Corp., Sumitomo Chemical and Syngenta. The international body combines several national-level or continent-wide organisations, each one having the same goals but differing according to local language and custom.

<span class="mw-page-title-main">Regulation of genetic engineering</span> Overview of the regulation of genetic engineering

The regulation of genetic engineering varies widely by country. Countries such as the United States, Canada, Lebanon and Egypt use substantial equivalence as the starting point when assessing safety, while many countries such as those in the European Union, Brazil and China authorize GMO cultivation on a case-by-case basis. Many countries allow the import of GM food with authorization, but either do not allow its cultivation or have provisions for cultivation, but no GM products are yet produced. Most countries that do not allow for GMO cultivation do permit research. Most (85%) of the world's GMO crops are grown in the Americas. One of the key issues concerning regulators is whether GM products should be labeled. Labeling of GMO products in the marketplace is required in 64 countries. Labeling can be mandatory up to a threshold GM content level or voluntary. A study investigating voluntary labeling in South Africa found that 31% of products labeled as GMO-free had a GM content above 1.0%. In Canada and the USA labeling of GM food is voluntary, while in Europe all food or feed which contains greater than 0.9% of approved GMOs must be labelled.

The International Association of Amusement Parks and Attractions (IAAPA) represents over 6,000 amusement-industry members in more than 100 countries worldwide and operates several global attractions-industry trade shows. Its annual IAAPA Expo in Orlando, Florida, is recognized as the world's largest attractions trade show in the number of attendees and exhibitors and providing members insight into current amusement trends, laws, operations and industry methodology. IAAPA also helps to promote guest-safety and ride-safety guidelines in conjunction with ASTM International and assists its members to uphold the highest amusement-industry safety and professional standards.

<span class="mw-page-title-main">Pfizer–BioNTech COVID-19 vaccine</span> Type of vaccine for humans

The Pfizer–BioNTech COVID-19 vaccine, sold under the brand name Comirnaty, is an mRNA-based COVID-19 vaccine developed by the German biotechnology company BioNTech. For its development, BioNTech collaborated with the American company Pfizer to carry out clinical trials, logistics, and manufacturing. It is authorized for use in humans to provide protection against COVID-19, caused by infection with the SARS-CoV-2 virus. The vaccine is given by intramuscular injection. It is composed of nucleoside-modified mRNA (modRNA) encoding a mutated form of the full-length spike protein of SARS-CoV-2, which is encapsulated in lipid nanoparticles. Initial advice indicated that vaccination required two doses given 21 days apart, but the interval was later extended to up to 42 days in the US, and up to four months in Canada.

<span class="mw-page-title-main">History of COVID-19 vaccine development</span> Scientific work to develop a vaccine for COVID-19

SARS-CoV-2, the virus that causes COVID-19, was isolated in late 2019. Its genetic sequence was published on 11 January 2020, triggering an urgent international response to prepare for an outbreak and hasten the development of a preventive COVID-19 vaccine. Since 2020, vaccine development has been expedited via unprecedented collaboration in the multinational pharmaceutical industry and between governments. By June 2020, tens of billions of dollars were invested by corporations, governments, international health organizations, and university research groups to develop dozens of vaccine candidates and prepare for global vaccination programs to immunize against COVID‑19 infection. According to the Coalition for Epidemic Preparedness Innovations (CEPI), the geographic distribution of COVID‑19 vaccine development shows North American entities to have about 40% of the activity, compared to 30% in Asia and Australia, 26% in Europe, and a few projects in South America and Africa.

<span class="mw-page-title-main">CureVac COVID-19 vaccine</span> Vaccine candidate against COVID-19

The CureVac COVID-19 vaccine was a COVID-19 vaccine candidate developed by CureVac N.V. and the Coalition for Epidemic Preparedness Innovations (CEPI). The vaccine showed inadequate results in its Phase III trials with only 47% efficacy. In October 2021 CureVac abandoned further development and production plans for CVnCoV and refocused efforts on a cooperation with GlaxoSmithKline.

The ImmunityBio COVID-19 vaccine, codenamed hAd5, is a non replicating viral vector COVID-19 vaccine developed by the United States-based pharmaceutical company ImmunityBio.